Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract of Amanita Muscaria. The company this morning announced that it has progressed the product to the stability testing phase.
Stability testing of the extract, known as AME-1, is to be conducted by CannaLabs, a licensed lab services firm. Stability tests are being conducted as a means of determining the shelf life and storage conditions for the extract as the company looks to ready for the eventual commercialization of the formulation.
The arrangement will also see testing methods developed for the raw inputs that are used in the extraction process to create AME-1. The process is to be used to assist the company in differentiating between other species and toxins, enabling Psyched Wellness to have a protocol for raw materials that is both safe and scientific in nature.
“After many months of pre clinical trials and other scientific work that is still ongoing, we have great confidence in our AME-1. Commencing the stability tests on the AME-1 is a big step that gets us closer to market.”
David Shisel, COO
Psyched Wellness last traded at $0.195 on the CSE.
Sponsored · First Phosphate Corp.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
